A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9

Cancer Letters
Li-Chun SunDavid H Coy

Abstract

Camptothecin (CPT) was conjugated to the N-terminal of a somatostatin analog (SSA) directly via a carbamate group and a basic N-terminal linking motif, D-Lys-D-Tyr-Lys-D-Tyr-D-Lys. This new CPT-SSA conjugate termed JF-10-81 was evaluated as a receptor-specific delivery system for its anti-invasive and anti-angiogenic activities. It was found that, in addition to blocking migration and invasion of highly invasive prostate cancer PC-3 cells, this conjugate also inhibited in vitro capillary-like tube formation of endothelial cells and in vivo angiogenesis in C57B1/6N female mice. JF-10-81 was found to block PC-3 cell attachment to various extracellular matrix components, mainly to vitronectin, the ligand of cell surface receptors integrin alphaVbeta3 and alphaVbeta5. Additionally, JF-10-81 reduced expression of integrins alphaVbeta3 and alphaVbeta5 on PC-3 cell surfaces, without effects on beta1 or any alphabeta1 heterodimers. This conjugate also inactivated phosphorylation of protein kinase B (PKB/Akt), down-regulated the expression of latent matrix metalloproteinase (MMP) -2 and MMP-9, but had little effect on MMP-3/-10. Meanwhile, membrane type-1 matrix metalloproteinase (MT1-MMP) and the tissue inhibitor of matrix metalloprote...Continue Reading

References

May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·E J BernhardR J Muschel
Feb 17, 1993·Journal of the National Cancer Institute·W J SlichenmyerS H Kaufmann
Oct 21, 1998·Oncogene·C C Kumar
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J O'Leary, F M Muggia
Aug 7, 1999·The Journal of Biological Chemistry·V ChaturvediB J Nickoloff
Sep 29, 1999·Cancer Chemotherapy and Pharmacology·M K ClementsS S Daoud
Jan 7, 2000·Biochemical and Biophysical Research Communications·Q ZhouF S Markland
Aug 26, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S Curran, G I Murray
Apr 6, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H KiarisG Halmos
May 12, 2001·Pathology Oncology Research : POR·A John, G Tuszynski
Jul 20, 2001·British Journal of Cancer·J C WatsonE A Woltering
Sep 5, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D KimJ Chung
Nov 17, 2001·Journal of Cancer Research and Clinical Oncology·N ChattopadhyayA Chatterjee
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Ayako NakashioTakashi Tsuruo
Mar 6, 2003·Bioorganic & Medicinal Chemistry Letters·Joseph A FuselierDavid H Coy
Jun 5, 2003·Nature Reviews. Cancer·Gabriele Bergers, Laura E Benjamin
Jun 5, 2003·Nature Reviews. Cancer·Raghu Kalluri
Aug 16, 2003·Endocrine Reviews·Jean Claude Reubi
Sep 25, 2003·Cancer Biotherapy & Radiopharmaceuticals·Eugene A Woltering
Feb 5, 2004·British Journal of Cancer·H Jin, J Varner
Apr 9, 2004·Pharmaceutical Research·Eric L Snyder, Steven F Dowdy
Jun 24, 2004·Seminars in Cell & Developmental Biology·Julian Downward
Aug 6, 2004·Journal of Medicinal Chemistry·Luciana MarinelliHorst Kessler
Oct 12, 2004·Experimental Neurology·Kevin J Whittlesey, Lonnie D Shea
Dec 14, 2004·Immunologic Research·Rahul K Patel, Chandra Mohan

❮ Previous
Next ❯

Citations

May 6, 2008·Cancer Biotherapy & Radiopharmaceuticals·Monique de VisserMarion de Jong
Jun 6, 2008·Endocrine-related Cancer·Hira Lal GoelLucia R Languino
Dec 2, 2009·Expert Opinion on Drug Delivery·Gábor Mezo, Marilena Manea
Jun 19, 2009·Medicinal Research Reviews·Yong Li, Paul J Cozzi
Jul 1, 2020·Journal of Travel Medicine·Mugen UjiieHajime Inoue
Oct 9, 2007·Cell Biology International·Jing-Feng GuoXiao-Feng Zhu
Jan 17, 2019·Oxidative Medicine and Cellular Longevity·Yu-Guo YuanIl-Keun Kong
Jan 4, 2019·BMC Research Notes·Bayan Al-DabbaghAmr Amin
May 26, 2017·Biomedicines·Yosi GiladGary Gellerman
Feb 9, 2019·Journal of Medicinal Chemistry·Brian H WhiteMark T Bilodeau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Biophysics of Adhesion

Alterations in cell adhesion can disrupt important cellular processes and lead to a variety of diseases, including cancer and arthritis. It is also essential for infectious organisms, such as bacteria or viruses, to cause diseases. Understanding the biophysics of cell adhesion can help understand these diseases. Discover the latest research on the biophysics of adhesion here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.